Clinical Relevance of the Use of Dentoxol for Oral Mucositis Induced by Radiotherapy: A Phase II Clinical Trial

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2022 Nov 7

PMID 36337310

Authors

Sebastian Sole

Sergio Becerra

Claudia Carvajal

Piero Bettolli

Hernan Letelier

Alejandro Santini

Lorena Vargas

Alexander Cifuentes

Francisco Larsen

Natalia Jara

Jorge Oyarzun

Eva Bustamante

Benjamin Martinez

David Rosenberg

Tomas Galvan

Affiliations

Soon will be listed here.

Abstract

Background: Severe oral mucositis associated with cancer therapy is a frequent complication that may affect a patient's systemic condition, resulting in interruption and/or prolongation of cancer therapy. Dentoxol is a medical solution in the form of a mouthwash that has been shown to result in statistically significant improvement in the prevention of severe oral mucositis. However, knowing the measures of the clinical significance of this therapy is important for accurate decision-making.

Aim: To describe the clinical impact of Dentoxol use in severe oral mucositis.

Methods: Clinical significance was measured using the results obtained in a randomized controlled clinical trial previously conducted by the same group of researchers. The measures of clinical significance evaluated were the absolute risk or incidence, relative risk, absolute risk reduction, relative risk reduction, number needed to treat, and odds ratio.

Results: The data obtained show that the impact of Dentoxol on reducing the severity of oral mucositis has important clinical relevance.

Conclusion: The results of this study justify the incorporation of Dentoxol mouth rinse into clinical protocols as a complement to cancer therapy to prevent and/or treat oral mucositis secondary to radiotherapy.

References

Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L . Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2011; 29(20):2815-20. DOI: 10.1200/JCO.2010.32.4103. View

Hong J, Chiang C, Tsao C, Lin P, McBride W, Wu C . Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol. 1999; 75(11):1421-7. DOI: 10.1080/095530099139287. View

Heboyan A, Avetisyan A, Skallevold H, Rokaya D, Marla V, Vardanyan A . Occurrence of Recurrent Aphthous Stomatitis (RAS) as a Rare Oral Manifestation in a Patient with Gilbert's Syndrome. Case Rep Dent. 2021; 2021:6648729. PMC: 8068538. DOI: 10.1155/2021/6648729. View

Lalla R, Sole S, Becerra S, Carvajal C, Bettoli P, Letelier H . Efficacy and safety of Dentoxol® in the prevention of radiation-induced oral mucositis in head and neck cancer patients (ESDOM): a randomized, multicenter, double-blind, placebo-controlled, phase II trial. Support Care Cancer. 2020; 28(12):5871-5879. PMC: 7686187. DOI: 10.1007/s00520-020-05358-4. View

Trotti A, Bellm L, Epstein J, Frame D, Fuchs H, Gwede C . Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66(3):253-62. DOI: 10.1016/s0167-8140(02)00404-8. View

Treister N, Sonis S . Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg. 2007; 15(2):123-9. DOI: 10.1097/MOO.0b013e3280523ad6. View

Elting L, Cooksley C, Chambers M, Garden A . Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007; 68(4):1110-20. DOI: 10.1016/j.ijrobp.2007.01.053. View

Sonis S . Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34(1):39-43. DOI: 10.1016/s1368-8375(97)00053-5. View

Lalla R, Peterson D . Oral mucositis. Dent Clin North Am. 2004; 49(1):167-84, ix. DOI: 10.1016/j.cden.2004.07.009. View

10.

Lalla R, Schubert M, Bensadoun R, Keefe D . Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer. 2006; 14(6):558-65. DOI: 10.1007/s00520-006-0050-9. View

11.

Rao N, Trotti A, Kim J, Schell M, Zhao X, Amdur R . Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014; 50(8):765-9. PMC: 4593395. DOI: 10.1016/j.oraloncology.2014.06.001. View

12.

Funk C . Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294(5548):1871-5. DOI: 10.1126/science.294.5548.1871. View

13.

Xun C, Thompson J, Jennings C, Brown S, Widmer M . Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994; 83(8):2360-7. View

14.

Riley P, Glenny A, Worthington H, Littlewood A, Fernandez Mauleffinch L, Clarkson J . Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors. Cochrane Database Syst Rev. 2017; 11:CD011990. PMC: 6486203. DOI: 10.1002/14651858.CD011990.pub2. View

15.

Wong K, Kuciejewska A, Sharabiani M, Ng-Cheng-Hin B, Hoy S, Hurley T . A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother Oncol. 2016; 122(2):207-211. PMC: 6157713. DOI: 10.1016/j.radonc.2016.06.015. View

16.

Lalla R, Sonis S, Peterson D . Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2007; 52(1):61-77, viii. PMC: 2266835. DOI: 10.1016/j.cden.2007.10.002. View

17.

Epperly M, Gretton J, Defilippi S, Greenberger J, Sikora C, Liggitt D . Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. Radiat Res. 2000; 155(1 Pt 1):2-14. DOI: 10.1667/0033-7587(2001)155[0002:morice]2.0.co;2. View

18.

Kraemer H, Morgan G, Leech N, Gliner J, Vaske J, Harmon R . Measures of clinical significance. J Am Acad Child Adolesc Psychiatry. 2003; 42(12):1524-9. DOI: 10.1097/00004583-200312000-00022. View

19.

Vesty A, Gear K, Biswas K, Wagner Mackenzie B, Taylor M, Douglas R . Oral microbial influences on oral mucositis during radiotherapy treatment of head and neck cancer. Support Care Cancer. 2019; 28(6):2683-2691. DOI: 10.1007/s00520-019-05084-6. View

20.

Hong B, Sobue T, Choquette L, Dupuy A, Thompson A, Burleson J . Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019; 7(1):66. PMC: 6482518. DOI: 10.1186/s40168-019-0679-5. View